Introduction
In 1990, Ludwig and Thiel 1 suggested that applying CD65 antibodies in addition to CD33 and CD13 when attempting to differentiate immunologically poorly differentiated acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL). Data since then have supported this mandate, albeit for reasons not apparent 10 years ago. In ALL, CD33, CD13 and CD65/65s show a differential pattern of distribution. CD33 and CD13 are more frequently detected in CD10-positive early Pre-B ALL, while CD65/65s (and CD15/15s) is more frequently present on leukemic lymphoblasts from patients with CD10-negative Pro-B (Pre-Pre-B) ALL.
2,3 (Paietta et al. Blood 2001; 98: 841a; #3494; abstract) Thus, the concomitant expression of CD33, CD13 and CD65/CD65s in a case of acute leukemia supports the diagnosis of AML. On the other hand, lack of CD65/65s expression in the presence of CD33+CD13 does not exclude the diagnosis of AML but requires that lymphoid-specific features, such as intracytoplasmic CD3 and CD22, be negative before such diagnosis is entertained. 4 In myeloid differentiation, appearance of the sialylated poly-N-acetyllactosamine, CD65s, parallels the loss of the precursor antigen, CD34. 5 We thus decided to utilize CD65s expression as a marker of myeloid blast cell maturation in AML patients enrolled in Eastern Cooperative Oncology Group (ECOG) AML treatment trials between 1986 and 1999. Using 30% CD65s-positive myeloblasts as the level of expression that identified CD65s low AML, we describe the biologic and clinical features of 198 adult patients with CD65s low AML in comparison with 513 patients whose myeloid leukemia population contained 430% CD65s positive myeloblasts (CD65s high AML).
Patients, materials and methods

Patients
Between 1986 and 1999, specimens from 1105 patients enrolled in seven ECOG AML treatment trials (E3483, PC486, E3489, E1490, E3993, E4995, E3997) were submitted to the ECOG immunophenotyping reference laboratory. This recent 13-year period coincides with the use of multiparameter flow cytometry in the ECOG reference laboratory. For 994 of 1105 (90%), a diagnostic immunophenotype could be established. For the remaining 10%, specimens submitted were inadequate for informative testing. For this analysis, exclusion criteria were as follows: (1) 179 patients were excluded because of limited immunophenotypic testing that did not allow any AML subdiagnosis; (2) 86 cases were excluded because immunophenotyping was consistent with acute promyelocytic (APL), megakaryocytic or erythroid leukemia; given the distinct treatment options for APL, this subtype was excluded and (3) 18 further patients were excluded because of an immunodiagnosis of early Pre-B, Pro-B or T-ALL. A total of 711 patients qualified for the analysis: 399 (56%) were entered on five treatment trials for patients 55 years or younger and 312 (44%) were entered on two trials for older AML (455 years of age). Until February 1998, patients accrued to ECOG leukemia trials were simultaneously entered on laboratory protocol E1485 that included written consent for immunophenotyping, cytogenetics and selected molecular studies. After the closure of this laboratory protocol, written consent for the collection and testing of bone marrow and blood samples was sought from each patient at the time they consented to participate in the clinical trial. All ECOG treatment and laboratory protocols were reviewed and approved by local institutional review boards.
All treatment protocols were for previously untreated patients with AML and included anthracycline and cytarabine regimens for complete remission (CR) induction. Induction and postremission results for some of the studies have been published. [6] [7] [8] [9] [10] Treatment protocols for patients 55 years or younger were: (a) E3483, on which patients were induced with one to two courses of daunorubicin 60 mg/m 2 IV per day for 3 days, cytosine arabinoside (ara-C) 200 mg/m 2 continuous infusion for 5 days plus 6-thioguanine 100 mg/m 2 orally every 12 h for 5 days. Remitting patients were randomized to either one course of intensive consolidation therapy with high-dose ara-C 3 gm/m 2 i.v. every 12 h days 1-6, plus amsacrine 100 mg/m 2 per day i.v. on days 7-9 or to maintenance therapy for 2 years with 6-thioguanine 40 mg/m 2 twice daily plus ara-C 60 mg/m 2 subcutaneously on day 5 of each week or to observation. Patients younger than 41 years of age with a histocompatible sibling were to undergo allogeneic transplantation. (b) PC486, a phase II pilot study of autologous bone marrow transplantation in first CR with 4-hydroperoxy-cyclophosphamide purged marrow. (c) E3489, a randomized phase III trial of postremission therapy in AML. 10 Following remission induction with standard doses of idarubicin and ara-C (3 and 7), complete responders were consolidated with the identical regimen (2 and 5) before being offered an allogeneic transplant if a donor was available or being randomized to autologous bone marrow transplantation (4-hydroperoxy-cyclophosphamide purging) or high-dose ara-C therapy. Randomization was stratified according to age, FABtype, cytogenetic risk group and the number of induction courses necessary. (d) E4995, a phase II study of intensified induction chemotherapy with 2 gm/m 2 of ara-C administered over 75-90 min every 12 h Â 6 doses on days 8-10 following a 3 and 7 induction with daunorubicin and standard dose ara-C. Patients in CR who had a donor were assigned to allogeneic peripheral blood stem cell transplantation (PBSCT). Patients without a donor were to receive two courses of high-dose ara-C 1 month apart followed by autologous PBSCT. (e) E3997, a study which evaluated the effect of recombinant interleukin-11 in combination with high-dose ara-C following remission induction with an identical regimen as used in E4995. It should be noted that several of these trials offered transplantation in a randomized or nonrandomized setting. Compliance with randomized treatment assignment was not considered in this analysis.
Treatment protocols for patients 455 years of age were: (a) E1490, a randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor (GM-CSF) in adult patients between 455 and 70 years of age. 8 Induction consisted of daunorubicin 60 mg/m 2 /day i.v. days 1-3 and ara-C 25 mg/m 2 i.v. push on day 1 followed by 100 mg/m 2 continuous infusion on days 1-7. On day 10, at hypoplasia without evidence of leukemia, patients were randomized to receive GM-CSF or placebo until neutrophil recovery. (b) E3993, a randomized trial between daunorubicin, idarubicin, or mitoxantrone plus standard dose ara-C for remission induction, which also evaluated the effect of GM-CSF priming. Consolidation consisted of ara-C 1.5 gm/m 2 i.v. over 1 h every 12 h for 12 consecutive doses (six doses for patients 70 years and older) with open label GM-CSF.
Morphologic review
Central morphology review of bone marrow slides and cytochemical stains was available in 636 (89%) patients. Morphologic diagnoses followed the guidelines established by the French-American-British classification system.
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Cytogenetic analysis Cytogenetic studies were performed by the individual ECOG institutions. Two karyotypes from each case were centrally reviewed by ECOG's Cytogenetics Subcommittee. For normal karyotypes to be acceptable, at least 20 metaphases from bone marrow had to be evaluated. Cytogenetic risk groups have been assigned as established in Slovak et al. 13 The favorable group included inv(16)/t(16;16)/del(16q) with or without other chromosome abnormalities, and t(8;21) without either del(9q) or part of a complex karyotype. The intermediate group included +8, loss of sex chromosome, +6, del(12p) and normal karyotype. The unfavorable group included À5/del(5q), À7/del(7q), inv(3q)/t(3;3), abnormalities including 11q23, del(20q), del(21q), del(9q), t(6;9), t(9;22), abnormal 17p, and complex karyotypes defined as three or more clonal abnormalities. The indeterminate group included fewer than three abnormalities without known prognostic association.
Immunophenotyping
Multiparameter flow cytometry was performed in ECOG's immunophenotyping reference laboratory. Bone marrow or peripheral blood samples were shipped to the laboratory from ECOG institutions on wet ice by overnight courier. Mononuclear cells were isolated by ficoll-hypaque density centrifugation. Antigen expression data reflect gated leukemic blast cells. Until 1996, blast cells were gated predominantly based on scatter characteristics. After 1996, blast cells were selected with the help of an antibody that distinguished the blasts from contaminating normal cells in multicolor flow cytometry, for example, CD34, CD117, HLA-DR, etc, which was added to every antibody tube in the testing panel. Antibody binding was evaluated on a FACScan or FACSCalibur and the Lysys II or CellQuest software program (Beckton-Dickinson, Mountainview, CA, USA; BD). Antigen expression patterns are described as the percentage of blast cells positive for the various antigens, calculated from the proportion of cells that stained with a given antibody with greater intensity than the brightest cells of the negative control or of nonstaining cells present in the cell population. The a priori definition of arbitrary cutoff levels of antigen expression to describe 'positivity' for a given antigen was purposely avoided. To compare the percentage of CD65s-positive cells with the intensity of CD65s expression, the mean fluorescence intensity of CD65s antibody binding was recorded to obtain an estimate of antigen density. In the absence of calibration of fluorescence measurements with a standard reference material for fluorescence intensity, we aimed at reproducibility of results by adjusting for background staining, crosstesting of antibody lots, monitoring of instrument settings, and by comparing patient samples against reference cell lines.
A panel of 49 monoclonal antibodies, which covered antigens of all hematopoietic cell lineages, was tested in varying frequencies over the 13-year period. To allow for comparability of flow cytometric results, a potential problem even when much shorter test periods are concerned, ECOG's immunophenotyping reference laboratory standardizes all antibodies by weekly testing against a balanced mixture of cell lines representing the various leukemia phenotypes (Pizzolo et al. Cytometry 1998; 128: #CT61; abstract). Two-and three-color analyses (fluorescein isothiocyanate, FITC; phycoerythrin; peridinin chlorophyll protein; Tri-Color; phycoerythrin-cyanine 5) were employed. The majority of antibodies were from BD, Immuno-tech/Beckman Coulter (Westbrook, ME, USA), Caltag Labs (South San Francisco, CA, USA), and Accurate Chemical & Scientific Corp (Westbury, NY, USA), unless otherwise indicated. The CD65s antibody VIM-2 was provided by Dr W Knapp, Institute of Immunology, Vienna, Austria. This antibody is commercially available (An der Grub, Kaumberg, Austria). Immunophenotyping included staining for intracytoplasmic and surface CD3 and CD22, terminal deoxynucleotidyl transferase (TdT) (FITC-conjugated monoclonal anti-human TdT-6 antibody from Supertechs, Bethesda, MD, USA), CD19, CD10, CD20, CD24, CD40, CD5, CD2, CD7, CD4, CD8 to exclude a lymphoid lineage affiliation, staining for glycophorin , CD36 and bloodgroup-H antigen (CD173) to evaluate erythroid markers, and CD41/61, CD62P, and CD42a together with CD36 to detect megakaryocytic antigens. 4 Myeloid antigens tested included myeloperoxidase, lactoferrin, CD33, CD13, CD65s, CD15, CD15s, CD11b, CD14. Uncommitted cell antigens were CD34, CD117, CD90, HLA-DR, CD45, CD38, CD71, CD25, CD122, CD56, CD11a, CD50, CD54, CD57, CD58, CD62L. P-glycoprotein was detected using two antibodies to surface epitopes, 4E3.16 (provided by Dr R Arceci, then Dana Farber Cancer Inst., Boston, MA, USA) and MRK-16 (Kamiya Biomedical Co., Thousand Oaks, CA, USA), which we found to yield equivalent results. Intracytoplasmic and intranuclear staining employed Fix&Perm for fixation and permeabilization (Caltag Labs).
Statistical comparisons were performed on the distribution of 19 of these antigens between CD65s low and CD65s high AML. These 19 particular antigens were chosen as follows: (a) except for CD117 and CD56, information on the expression of these antigens was available in at least 75% of cases in each study group; and (b) although data on CD117 and CD56 expression were available only in 30% (222 patients) and 35% of patients (247 patients), respectively, with even distribution between study groups, analysis of these antigens was included given their proposed prognostic significance in AML. 4 CD65s low AML was defined by CD65s expression on 30% or less of gated leukemic myeloblasts. While not derived from retrospective outcome analysis, this cutoff point was based on the degree of myeloid maturation of blast cells and thus should not be considered arbitrary (see Results). In this analysis, CD65s was the only antigen that was dichotomized; for all other antigens, no cutoff point was used. We chose to characterize high and low levels of CD65s because of concerns that if CD65s were considered as a continuous variable, extreme values (very close to 0 or to 100%) would drive the association between CD65s level and both biologic and clinical parameters.
CD65s and related antigens
The antibody VIM-2 uniquely binds to the sialylated form of the carbohydrate antigen CD65, a type 2 carbohydrate chain with four lactosamine repeats and one fucose bound to the penultimate N-acetylglucosamine and one terminal a-2,3-linked N-acetyl-neuraminic acid; thus, only VIM-2 carries the designation of CD65s antibody.
14 The other CD65 family comprises antibodies such as VIM-8, VIM-11, HE10, 88H7, which all bind preferentially to the asialoganglioside of the VIM-2 decasaccharide. Despite the structural similarity, different reaction patterns are found with CD65s/CD65 antibodies. In normal peripheral blood and bone marrow, VIM-2 binds to all stages of myeloid differentiation as well as cells of the monocytic lineage, while CD65 antibodies do not show the same reactivity with monocytes. 15 With respect to leukemic cells, VIM-2 reacts with a fraction of Pro-B or Pre-Pre-B lymphoblasts, while CD65 antibodies do not. 14, 15 The distinction between neuraminidasesensitive and -resistant reactivity in the CD65 family is reminiscent of the separation of CD15 from CD15s, another group of carbohydrate-reactive antibodies.
14 Analogous to VIM-2, there exists only one strictly specific CD15s antibody, CSLEX-1, whereas numerous CD15 antibodies are available.
14 The differential reactivity of CD15s vs CD15 antibodies with leukemic promyelocytes is a diagnostic characteristic for this disease that reflects increased sialylation. 16 The same observation can be made in APL cells when VIM-2 is tested against CD65 antibodies.
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Statistical analyses
Except for E3483, which was initiated before the establishment of ECOG's immunophenotyping reference laboratory in 1985, 95-99% (dependent on study) of all patients entered on a treatment protocol are captured for immunophenotyping. Of the samples submitted between 1986 and 1999 on the seven ECOG trials under consideration, 10% did not yield an informative immunophenotype. Antigen expression levels and other continuous variables were compared using the Wilcoxon rank-sum test. Data are summarized by the median and quartiles of the observed values, where the median is the middle value of the ordered data set and the quartiles are the 25th and 75th percentiles. To adjust for multiple comparisons of antigens, the Bonferroni correction was used. Therefore, results are presented as significant at the 0.05 level if the nominal P-value is less than 0.0026. Differences in median antigen expression of 10% or less of gated blast cells were not considered biologically meaningful given the inherent variability of flow cytometric measurements. Analyses of 2 Â 2 tables were performed using Fisher's exact test. Multiple logistic regression was used to model response to therapy. Distribution of CD65s low cases over age categories was assessed using the Kruskal-Wallis test. The associations between level of AML differentiation and categorical variables such as cytogenetic risk group, FAB subtype, and achievement of CR, were assessed using Fisher's exact test. Overall survival was measured from date of study registration to date of death or date last known alive. The log-rank test for censored survival data were used to assess differences in survival between patient groups. All P-values reflect two-sided tests, and all P-values presented are nominal P-values.
Results
Of the 711 AML patients included into this analysis, 198 (28%) met the criteria of CD65s low AML. Although the arbitrary threshold recommended 17 and most commonly utilized for defining surface antigen positivity lies at 20% positive blast cells, we deviated from this approach for the definition of CD65s low AML with the following rationale: ECOG has always been a proponent of biologically derived rather than arbitrary cutoff points for individual markers when analyzing antigen expression with respect to outcome. 18 Given the ubiquitous demonstration of myeloperoxidase by antibody staining in all subgroups of AML, 4, 19 we decided to determine the upper limit of CD65s-positive blast cells in the definition of CD65s low AML in comparison to the level of maturation suggested by the level of myeloperoxidase expression. We observed that in patients with 0-20% CD65s-positive myeloblasts, the median of myeloperoxidase-expressing blasts by flow cytometry were 39%; in patients with 0-30% CD65s positive myeloblasts, myeloperoxidase expression was found in a median of 39.5% blast cells; in patients with CD65s expression in 0-40% myeloblasts, myeloperoxidase-positive blasts averaged 50.5%. Therefore, a choice of 20-30% CD65s positive myeloblasts would appear to provide a robust grouping of less mature disease. To evaluate whether the loss of CD65s with progressive maturation was also reflected in lower antigen density, we compared the intensity of fluorescence staining with the VIM-2 antibody with the percentage of VIM-2 staining blast cells in a subset of 106 cases in which both measures were available. The mean fluorescence channel was significantly different between those cases called CD65s In terms of on-study characteristics of CD65s low in comparison with CD65s high AML patients. CD65s low patients were markedly older than the CD65s high AML group (median 59 vs 48 years, Po0.0001 by the Wilcoxon rank-sum test). An analysis of the distribution of CD65s low cases over age categories using the Kruskal-Wallis test revealed that under the age of 50 years, the incidence of CD65s low AML was 20% (0% in patients in their teens), between 50 and 69 years of age, the incidence was 32%, and this figure rose to 46% in patients in their 70s and to 67% in patients in their 80s (Po0.0001).
There was no difference in the male to female ratio (1.14). White blood cell counts at presentation were significantly lower in the CD65s low group, with a median of 8. high AML (P ¼ 0.0013). However, overall, the distribution of cytogenetic risk groups did not differ between CD65 low and CD65s high AML (P ¼ 0.14). Of CD65s low AML patients, 46% achieved a CR compared with 55% of more mature AML (P ¼ 0.62). When stratified by age, patients 455 years old and presenting with CD65s low immunophenotype had a CR rate of 33% compared with 44% in older patients with more mature immunophenotype (P ¼ 0.055), which is suggestive of an association. The level of myeloid differentiation had no such effect in younger patients (P ¼ 0.8). 
Overall survival was not affected by CD65s status in patients 55 years or younger (P ¼ 0.5) or 455 years of age (P ¼ 0.4).
Discussion
The most significant results from our study are that (a) CD65s low AML is strongly associated with age 455 years (P ¼ 0. 000004); (b) the probability of presenting with CD65s low AML increases with age; (c) low CD65s expression in AML is an indicator of morphologically (high frequency of M0, M1) and antigenically poorly differentiated disease, characterized by a high incidence of early differentiation antigens (such as CD34, CD117, TdT) and a low incidence of late maturation antigens (such as CD15, CD11b, CD14); (d) CD65s low AML lacks expression of lymphoid-affiliated antigens, other than TdT; (e) it is not associated with increased levels of P-glycoprotein or unfavorable cytogenetics; and (f) low CD65s expression unfavorably affected outcome, albeit without reaching statistical significance, only in patients over the age of 55 years.
Improved supportive care continues to permit increasingly aggressive therapeutic measures, such as high-dose ara-c or allogeneic stem cell transplantation, at older ages, thus redefining 'older'. The ECOG trials included in this analysis as well as most studies on older adult AML available from the literature, however, use 55 years as cutoff age. Apart from agerelated toxicity considerations, a distinct biology of AML in older individuals is suggested from both the age-specific exponential rise in incidence rate above the age of 50 years 23 and the inferior results obtainable in older AML by conventional chemotherapy when compared with younger patients. 24 Head 25 developed a classification of AML by dividing into true de novo AML and AML related to myelodysplasia (MDS-related AML), in which the majority of AML in older adults was included in the MDS-related group. The rationale of his model, among other considerations, was based on common cytogenetic abnormalities shared by MDS and older AML, in particular, aberrations of chromosomes 5 and 7, an observation made earlier by Rowley et al. 26 Trilineage dysplasia may 27, 28 or may not 29 be more frequent in older AML and causally related to the poorer outcome in this patient population. More recent studies have suggested that the resistance experienced in older adult and MDS-related or secondary AML may, at least in part, derive from the presence of functionally active multidrug-resistance Pglycoprotein 30 or diminished apoptotic responses when exposed to ara-c or daunomycin. 31 However, these conclusions have not remained uncontested. 32, 33 Although AML in older adults is far from being a homogeneous entity, there appears to be an increased frequency of less differentiated leukemias, whether diagnosed by morphologic criteria 34 or by antigenic characteristics such as an increased frequency of CD34 expression. 35 Conversely, AML with FAB-type M0, the subtype with the least morphologic differentiation, 12 develops preferentially in older patients (Z60 years of age). [36] [37] [38] [39] [40] [41] [42] Historically, but even in the recent WHO classification, 43 immunophenotypically minimally differentiated AML has been considered synonymous with FAB M0. Recent reviews of laboratory findings and proposals for new diagnostic criteria of minimally differentiated AML have focused on better defining AML-M0. 44, 45 As discussed elegantly by Stasi and Amadori, 44 FAB M0 is heterogeneous with respect to morphology, cytochemistry, immunophenotype, and cytogenetics, because of the lack of a specific marker or other biologic feature that could identify this FAB subtype as a distinct disease entity. It would be tempting to suggest that CD65s could be that antigen, the lack of which characterizing AML M0. Although several clinicobiological features attributed to AML M0 were not observed in CD65s low AML, such as a higher incidence of unfavorable cytogenetics when compared to more mature AML, excessive expression of P-glycoprotein, or a high frequency of lymphoid-affiliated antigens, 38, 39, 41, 44, 46, 47 there is strong evidence in favor of CD65s as a hallmark of myeloblast maturation.
With respect to morphology, 57% of CD65s low cases showed insignificant morphologic differentiation, a characteristic feature of FAB subgroups M0 or M1. 11, 12, 48 Antigenic features repeatedly observed in FAB-M0 44, 49 and associated with CD65s low AML in this study were the expression of the stem cell markers CD34, HLA-DR, CD117 and TdT. Of interest, CD7, an antigen expressed on CD34 + myeloid precursor cells in normal bone marrow, 50, 51 and found with increased frequency in some 44, 52 but not all studies of AML-M0, 47 was not associated with CD65s low but rather with CD65s high AML ( Table 1 ). In support of our concept of an association between morphologically poorly differentiated AML and low CD65s expression, Thalhammer-Scherrer et al 49 found CD65s positivity (defined as Z20% of blasts) in 10% of M0 cases compared with 57.6% in other morphologic AML subtypes. Legrand et al 53 observed that a panmyeloid phenotype, characterized by the combined expression of myeloperoxidase, CD33, CD13 and CD65s, was associated with a significantly higher CR rate and longer survival when compared with a less than complete myeloid phenotype. The myeloid antigen most consistently absent in the less than complete phenotype was CD65s and patients with incomplete myeloid phenotype were older. In a recently published series of M0 cases from a European multicenter study, 41 CD65s expression was positive (defined as at least 20% of blasts) in 33% of adults between the ages of 16-60 years and in 22% of patients 460 years of age. In accord with our hypothesis, this observation is interpretable as a decrease in myeloblast maturation among M0 AML patients with increasing age.
Without exception, AML-M0, despite representing a conglomerate of immature phenotypes, has been associated with poor prognosis. 36, 37, 41, 52 However, while it is obvious that AML-M0 occurs predominantly in older adults, as discussed before, response rate and response duration across the board have been compared to AML patients of all ages, and statistical analyses have not been adjusted for this established significant prognostic covariate. To the point, in a series of M0 cases reported from Taiwan, 38 only the adult patients (median age of 57 years) showed poorer outcome when compared to non-M0 AML; the pediatric M0 cohort did not demonstrate a significant difference in clinical response when compared to an age-adjusted control group. This observation suggests that the inferior outcome of morphologically poorly differentiated AML may be the result of older age. Analogously, our current analysis in 4700 patients suggests that immunophenotypically poorly differentiated AML, based on low CD65s expression, is associated with age 455 years. In fact, the distribution of CD65s low AML over age categories in decades clearly demonstrated that older age increased the probability of developing poorly differentiated, CD65s low AML (Po0.0001). The most prominent rise in the incidence of CD65s low AML occurred above the age of 70 years. This biologic age cutoff correlates well with the clinical experience that CR rates drop sharply in patients older than 70. 35, [54] [55] [56] While the CD65s low antigen profile did not affect response to chemotherapy in patients under the age of 55 years, it reduced the likelihood to achieve CR in the older age group. Although this association was weak (P ¼ 0.055), it was intriguing given that the results in the older patient population were quite different from the concordant findings in younger patients. This Low CD65s expression in older AML adults E Paietta et al may suggest that antigenic immaturity of leukemic blast cells is an important component of the poor prognosis that we observe in older AML patients. Whenever a new leukemia syndrome is described, one must consider the usefulness of its associated immunophenotype for the monitoring of minimal residual disease (MRD). Recent studies have suggested a novel risk classification for AML based on MRD detection. 57, 58 The overall leukemia-associated immunophenotype (LAIP) for CD65s low AML, unfortunately, has only limited utility in this respect since it resembles too much a normal myeloid precursor cell, with expression of CD34, CD117 and lack of expression of more mature myeloid antigens such as CD15 and CD11b. 4 In situations like this, it is difficult to report reliably on the presence of residual disease unless the incidence of these cells is found to be in excess to that expected for myeloid progenitor cells with equivalent immunophenotype in normal bone marrow. In the individual patient, however, it may be possible to exploit the CD65s low AML LAIP for MRD purposes, namely when other antigenic aberrancies are present, such as the expression of TdT by the leukemic myeloblasts, which is significantly more common in CD65s low than CD65s high AML.
